Table 3.

Quantitative description of adverse drug events (ADEs)

	Pre-stage (n = 168)	Post-stage (n = 243)	Total (n = 411)
Patients affected by ADEs	13 (7.7%)	23 (9.4%)	36
Gender
Male	1 (0.6%)	8 (3.3%)	9
Female	12 (7%)	15 (6.1%)	27
Age, years
> 65	1 (0.6%)	2 (0.8%)	3
≤ 65	12 (7%)	21 (8.6%)	33
Clinical severity of ADEs
Low	10 (5.9%)	15 (6.1%)	25
Moderate	3 (1.7%)	8 (3.2%)	11
Preventability of ADEs
Preventable	6 (3.5%)	10 (4.1%)	16
Non-preventable	7 (4.1%)	13 (5.3%)	20
Medication classes associated with ADEs
Anti-infective	0	1	1
Blood and blood-forming organs	0	1	1
Skin	0	1	1
Respiratory system	1	0	1
Gastrointestinal system (laxative)	2	1	3
Nervous system	1	6	7
Antiepileptics	1	1	2
Analgesics, opioid	0	2	2
Analgesics, non-opioid	0	1	1
Antipsychotics	0	1	1
Antidepressants	0	1	1
Cardiovascular system	9	13	22
Diuretics	3	8	11
Angiotensin-converting enzyme inhibitors	3	0	3
Antithrombotic, antiplatelet drugs	2	1	3
Calcium-channel blockers	0	2	2
Beta-adrenoceptor blockers	0	1	1
Angiotensin receptor antagonists	0	1	1
Antithrombotic, factor Xa inhibitor	1	0	1
Most common symptoms of ADEs
Reduced renal function, or acute kidney injury	2	3	5
Oedema or swelling	2	3	5
Diarrhoea	2	2	4
Uncontrolled blood pressure (high or low)	2	2	4
Drowsiness or dizziness	1	2	3

Bold values indicate the total number for this category

ADEs adverse drug events